vs
Side-by-side financial comparison of BIOMARIN PHARMACEUTICAL INC (BMRN) and Meritage Homes CORP (MTH). Click either name above to swap in a different company.
Meritage Homes CORP is the larger business by last-quarter revenue ($1.4B vs $874.6M, roughly 1.6× BIOMARIN PHARMACEUTICAL INC). Meritage Homes CORP runs the higher net margin — 17.7% vs -5.3%, a 23.0% gap on every dollar of revenue. On growth, BIOMARIN PHARMACEUTICAL INC posted the faster year-over-year revenue change (17.0% vs 10.5%). BIOMARIN PHARMACEUTICAL INC produced more free cash flow last quarter ($58.9M vs $-225.4M).
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Meritage Homes Corporation is a publicly traded American real estate development company that constructs a variety of single-family detached homes across the United States. It is the fifth largest home builder in the United States, based on 2023 home sales. The company also develops active adult communities and luxury real estate in Arizona.
BMRN vs MTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2022
| Metric | | |
|---|---|---|
| Revenue | $874.6M | $1.4B |
| Net Profit | $-46.6M | $250.1M |
| Gross Margin | 68.5% | 31.5% |
| Operating Margin | -5.1% | 23.5% |
| Net Margin | -5.3% | 17.7% |
| Revenue YoY | 17.0% | 10.5% |
| Net Profit YoY | -137.3% | 49.4% |
| EPS (diluted) | $-0.22 | $6.77 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $874.6M | — | ||
| Q3 25 | $776.1M | — | ||
| Q2 25 | $825.4M | — | ||
| Q1 25 | $745.1M | — | ||
| Q4 24 | $747.3M | — | ||
| Q3 24 | $745.7M | — | ||
| Q2 24 | $712.0M | — | ||
| Q1 24 | $648.8M | — |
| Q4 25 | $-46.6M | — | ||
| Q3 25 | $-30.7M | — | ||
| Q2 25 | $240.5M | — | ||
| Q1 25 | $185.7M | — | ||
| Q4 24 | $124.9M | — | ||
| Q3 24 | $106.1M | — | ||
| Q2 24 | $107.2M | — | ||
| Q1 24 | $88.7M | — |
| Q4 25 | 68.5% | — | ||
| Q3 25 | 82.0% | — | ||
| Q2 25 | 81.8% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 81.8% | — | ||
| Q3 24 | 74.7% | — | ||
| Q2 24 | 81.7% | — | ||
| Q1 24 | 80.7% | — |
| Q4 25 | -5.1% | — | ||
| Q3 25 | -6.0% | — | ||
| Q2 25 | 33.5% | — | ||
| Q1 25 | 30.0% | — | ||
| Q4 24 | 21.6% | — | ||
| Q3 24 | 15.3% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 13.6% | — |
| Q4 25 | -5.3% | — | ||
| Q3 25 | -4.0% | — | ||
| Q2 25 | 29.1% | — | ||
| Q1 25 | 24.9% | — | ||
| Q4 24 | 16.7% | — | ||
| Q3 24 | 14.2% | — | ||
| Q2 24 | 15.1% | — | ||
| Q1 24 | 13.7% | — |
| Q4 25 | $-0.22 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $1.23 | — | ||
| Q1 25 | $0.95 | — | ||
| Q4 24 | $0.65 | — | ||
| Q3 24 | $0.55 | — | ||
| Q2 24 | $0.55 | — | ||
| Q1 24 | $0.46 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $272.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.1B | $3.4B |
| Total Assets | $7.6B | $5.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $942.8M | — | ||
| Q3 24 | $675.4M | — | ||
| Q2 24 | $972.1M | — | ||
| Q1 24 | $747.0M | — |
| Q4 25 | $6.1B | — | ||
| Q3 25 | $6.1B | — | ||
| Q2 25 | $6.0B | — | ||
| Q1 25 | $5.8B | — | ||
| Q4 24 | $5.7B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $5.3B | — | ||
| Q1 24 | $5.1B | — |
| Q4 25 | $7.6B | — | ||
| Q3 25 | $7.6B | — | ||
| Q2 25 | $7.5B | — | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $6.9B | — | ||
| Q2 24 | $7.1B | — | ||
| Q1 24 | $6.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.6M | $-219.0M |
| Free Cash FlowOCF − Capex | $58.9M | $-225.4M |
| FCF MarginFCF / Revenue | 6.7% | -16.0% |
| Capex IntensityCapex / Revenue | 4.7% | 0.5% |
| Cash ConversionOCF / Net Profit | — | -0.88× |
| TTM Free Cash FlowTrailing 4 quarters | $725.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.6M | — | ||
| Q3 25 | $368.7M | — | ||
| Q2 25 | $185.3M | — | ||
| Q1 25 | $174.4M | — | ||
| Q4 24 | $185.6M | — | ||
| Q3 24 | $221.5M | — | ||
| Q2 24 | $118.8M | — | ||
| Q1 24 | $47.0M | — |
| Q4 25 | $58.9M | — | ||
| Q3 25 | $340.2M | — | ||
| Q2 25 | $168.2M | — | ||
| Q1 25 | $157.6M | — | ||
| Q4 24 | $166.1M | — | ||
| Q3 24 | $203.0M | — | ||
| Q2 24 | $97.4M | — | ||
| Q1 24 | $20.9M | — |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 43.8% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 22.2% | — | ||
| Q3 24 | 27.2% | — | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 4.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.53× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
MTH
| Home Building | $1.4B | 100% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $9.8M | 1% |
| Financial Service | $5.1M | 0% |
| Land Closing | $3.4M | 0% |
